UY28931A1 - Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis - Google Patents

Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis

Info

Publication number
UY28931A1
UY28931A1 UY28931A UY28931A UY28931A1 UY 28931 A1 UY28931 A1 UY 28931A1 UY 28931 A UY28931 A UY 28931A UY 28931 A UY28931 A UY 28931A UY 28931 A1 UY28931 A1 UY 28931A1
Authority
UY
Uruguay
Prior art keywords
angiogenesis
diseases associated
proliferative disorders
pirrolotriazine
derivatives
Prior art date
Application number
UY28931A
Other languages
English (en)
Inventor
Julie A Dixon
Harold C E Kluender
Jianmei Fan
Benjamin D Jones
Barton Phillips
Dr Michael Brands
Steven Magnuson
Catherine Brennan
Karl Miranda
Brent Chandler
Andrea Mcclure
Wenlang Fu
Donald Bierer
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of UY28931A1 publication Critical patent/UY28931A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

La presente invención se refiere a nuevos compuestos con estructura de pirrolotriazina, a composiciones farmacéuticas que contienen tales compuestos y al uso de esos compuestos y composiciones para la prevención y/o tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogénesis.
UY28931A 2004-06-03 2005-05-30 Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis UY28931A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57665204P 2004-06-03 2004-06-03
US62653104P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
UY28931A1 true UY28931A1 (es) 2005-12-30

Family

ID=34971944

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28931A UY28931A1 (es) 2004-06-03 2005-05-30 Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis

Country Status (31)

Country Link
US (3) US7563791B2 (es)
EP (1) EP1765823B1 (es)
JP (1) JP4958772B2 (es)
KR (1) KR101235602B1 (es)
CN (1) CN1993361B (es)
AR (1) AR049138A1 (es)
AT (1) ATE462708T1 (es)
AU (1) AU2005252217B2 (es)
BR (1) BRPI0510848A (es)
CA (1) CA2569396C (es)
DE (1) DE602005020293D1 (es)
EC (1) ECSP067043A (es)
ES (1) ES2342722T3 (es)
GT (1) GT200500137A (es)
HK (1) HK1109141A1 (es)
HN (1) HN2005000255A (es)
IL (1) IL179264A0 (es)
MA (1) MA28689B1 (es)
MX (1) MX279139B (es)
MY (1) MY145077A (es)
NO (1) NO20070049L (es)
NZ (1) NZ551742A (es)
PE (1) PE20060243A1 (es)
PH (1) PH12006502386B1 (es)
RU (1) RU2401269C2 (es)
SG (1) SG127661A1 (es)
SV (1) SV2006002134A (es)
TW (1) TW200608979A (es)
UY (1) UY28931A1 (es)
WO (1) WO2005121147A1 (es)
ZA (1) ZA200700011B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005037499A1 (de) * 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
MX2008007103A (es) 2005-12-02 2008-09-12 Bayer Healthcare Llc Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis.
SMP200800041B (it) 2005-12-21 2009-07-14 Novartis Ag Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori
EP1882475A1 (en) * 2006-07-26 2008-01-30 Novartis AG Method of treating disorders mediated by the fibroblast growth factor receptor
US7912582B1 (en) * 2007-05-03 2011-03-22 Innovation Associates, Inc. Robotic prescription filling system
NZ583790A (en) 2007-09-10 2012-04-27 Cipla Ltd Process for the preparation the raf kinase inhibitor sorafenib and intermediates for use in the process
CN101820762B (zh) * 2007-09-25 2014-07-30 拜耳保健公司 透过抑制极光激酶而用于治疗癌症的吡咯并三嗪衍生物
EP2085397A1 (en) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
CN103929961A (zh) * 2011-06-20 2014-07-16 美国阿尔茨海默病研究所公司 化合物及其治疗应用
KR20140036269A (ko) 2011-07-01 2014-03-25 바이엘 인텔렉쳐 프로퍼티 게엠베하 Alk1 억제제로서의 히드록시메틸아릴-치환된 피롤로트리아진
EP2791143B1 (en) 2011-12-15 2016-02-24 Bayer Intellectual Property GmbH Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
US9475815B2 (en) 2012-02-23 2016-10-25 Bayer Intelletual Property Gmbh Substituted benzothienyl-pyrrolotriazines and uses thereof
WO2015193263A1 (en) * 2014-06-17 2015-12-23 Chiesi Farmaceutici S.P.A. Indolizine derivatives as phoshoinositide 3-kinases inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
CA3008171A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
AU2017228398A1 (en) * 2016-03-03 2018-10-18 Cornell University Small molecule IRE1-alpha inhibitors
KR20230111268A (ko) 2016-03-28 2023-07-25 인사이트 코포레이션 Tam 억제제로서 피롤로트리아진 화합물
WO2018161033A1 (en) * 2017-03-02 2018-09-07 Wright, Adrian Small molecule ire1-alpha inhibitors
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
EP3988552A1 (en) 2017-09-27 2022-04-27 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
AR117600A1 (es) 2018-06-29 2021-08-18 Incyte Corp Formulaciones de un inhibidor de axl / mer
JP2022516057A (ja) 2018-12-31 2022-02-24 バイオメア フュージョン，エルエルシー メニン－ｍｌｌ相互作用の不可逆的阻害剤
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
US20230104574A1 (en) 2019-05-13 2023-04-06 Relay Therapeutics, Inc. Fgfr inhibitors and methods of use thereof
AU2020355359B2 (en) * 2019-09-26 2023-08-24 Shenzhen Targetrx, Inc. Substituted aromatic fused ring derivative and composition comprising same, and use thereof
CN113912628B (zh) * 2020-07-10 2023-05-02 北京范恩柯尔生物科技有限公司 三嗪类化合物及其组合物和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000071129A1 (en) 1999-05-21 2000-11-30 Bristol-Myers Squibb Company Pyrrolotriazine inhibitors of kinases
BR0115446A (pt) * 2000-11-17 2005-08-09 Bristol Myers Squibb Co Processos para tratamento de condições associadas a quinase p38 e compostos pirrolotriazina úteis como inibidores de quinase
WO2004013145A1 (en) * 2002-08-02 2004-02-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1694686A1 (en) 2003-12-19 2006-08-30 Takeda San Diego, Inc. Kinase inhibitors
UY28931A1 (es) * 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7405213B2 (en) 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
US7514435B2 (en) 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
MX2008007103A (es) * 2005-12-02 2008-09-12 Bayer Healthcare Llc Derivados 4-amino-pirrolotriazina sustituidos, útiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis.
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN101820762B (zh) * 2007-09-25 2014-07-30 拜耳保健公司 透过抑制极光激酶而用于治疗癌症的吡咯并三嗪衍生物

Also Published As

Publication number Publication date
TW200608979A (en) 2006-03-16
EP1765823B1 (en) 2010-03-31
US20070208013A1 (en) 2007-09-06
BRPI0510848A (pt) 2007-11-27
SV2006002134A (es) 2006-10-04
DE602005020293D1 (de) 2010-05-12
ZA200700011B (en) 2008-11-26
RU2401269C2 (ru) 2010-10-10
AR049138A1 (es) 2006-06-28
IL179264A0 (en) 2007-03-08
MX279139B (es) 2010-09-21
CA2569396C (en) 2011-12-20
PH12006502386B1 (en) 2010-12-23
HN2005000255A (es) 2010-09-17
ES2342722T3 (es) 2010-07-13
AU2005252217B2 (en) 2011-05-12
SG127661A1 (en) 2007-01-30
HK1109141A1 (en) 2008-05-30
AU2005252217A1 (en) 2005-12-22
JP4958772B2 (ja) 2012-06-20
GT200500137A (es) 2006-05-18
ATE462708T1 (de) 2010-04-15
RU2006147237A (ru) 2008-07-20
US20100075958A1 (en) 2010-03-25
CA2569396A1 (en) 2005-12-22
US20130225809A1 (en) 2013-08-29
MXPA06013457A (es) 2007-03-01
EP1765823A1 (en) 2007-03-28
MY145077A (en) 2011-12-15
US7563791B2 (en) 2009-07-21
NO20070049L (no) 2007-01-30
NZ551742A (en) 2010-08-27
JP2008501703A (ja) 2008-01-24
MA28689B1 (fr) 2007-06-01
KR101235602B1 (ko) 2013-02-21
PE20060243A1 (es) 2006-04-21
ECSP067043A (es) 2006-12-29
CN1993361A (zh) 2007-07-04
WO2005121147A1 (en) 2005-12-22
KR20070035028A (ko) 2007-03-29
CN1993361B (zh) 2010-05-26
US8338595B2 (en) 2012-12-25

Similar Documents

Publication Publication Date Title
UY28931A1 (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY26130A1 (es) Compuestos para tratar la obesidad
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
WO2007092065A3 (en) Compounds and compositions as lxr modulators
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
TW200602330A (en) Compounds and compositions as PPAR modulators
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
TW200745122A (en) New compounds I
ECSP034810A (es) Derivados heterociclilalcoxi-, -alquiltio- y - alquilaminobenzazol tales como ligandos 5-hidroxitriptamina-6
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
TW200745133A (en) New compounds II
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
WO2004098522A3 (en) Gemini vitamin d3 compounds and methods of use thereof
UY29756A1 (es) Derivados de 5-piridazinil-1-azabiciclo(3.2.1) octano, su preparación y su aplicación en terapéutica.
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
DOP2005000109A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenisis

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140310